403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Antibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, At 15.8% CAGR: Dimension Market Research
| Report Highlights | Details |
| Market Size (2024) | USD 13.7 Bn |
| Forecast Value (2033) | USD 51.2 Bn |
| CAGR (2024-2033) | 15.8% |
| North America Revenue Share (2024) | 42.7% |
| The US Market Size (2024) | USD 4.9 Bn |
| Historical Data | 2018 - 2023 |
| Forecast Data | 2024 - 2033 |
| Base Year | 2023 |
| Estimate Year | 2024 |
| Segments Covered | By Product, By Target Type, By Technology, By Payload Type, By Application, By End-User |
| Regional Coverage | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Growth Drivers
- Technological Advancements: New linkers and potent payloads, as well as improvements in the conjugation strategies, have resulted in safety and efficacy improvements that fuel the ADC market's growth. Increasing Cancer Prevalence: The growth in cancer incidence positively affects the ADC market, as these drugs target cytotoxic agents directly at cancer cells, enhancing patients' quality of life and responding to the demand for personalized medicine.
Restraints
- High Development Costs: It is due to the complexity of their creation that ADCs present high development and manufacturing costs, which are poorly designed for the final consumer and bear great financial risks to the pharma companies. Regulatory Challenges: Adverse regulatory requirements that target approval of ADCs require serious clinical tests before being accessed in the market and can also be very expensive which may limit market growth.
Growth Opportunities
- Emerging Markets: The Asia-Pacific region, Latin American and the Middle East are opportunities to tap owing to the enhancement of medical facilities and augmented cancer consciousness. Market expansion is also boosted by such factors as favorable regulations. Combination Therapies: Cohort utilization of ADCs with other therapy modalities such as immunotherapy or Check Point inhibitors augments therapeutic efficacy, raising the response rates and extent of ADC usage.
Market Analysis
KADCYLA is projected to dominate the global ADC market, holding 24.1% of the market share in 2024. This ADC has been tested for the treatment of HER2-positive breast cancer by conjugating the drug with TRASTUZUMAB together with the cytotoxic agent DM1 and it was observed that the size of the tumor reduced and progression free survival increased.
Market eclipses for several indications and definite clinical trial support has contributed towards establishing a rigid market. Further marketing and distribution strongly help Roche to guarantee KADCYLA's market leadership in the ADC segment.
Purchase the Competition Analysis Dashboard Today:
Antibody Drug Conjugate Market Segmentation
By Product
- KADCYLA ENHERTU ADCETRIS PADCEV TRODELVY POLIVY Other Products
By Target Type
- HER2 Antibodies CD22 Antibodies CD30 Antibodies CD33 Antibodies CD79b Antibodies Other Target Types
By Technology
- Type
- Cleavable Linker Antibodies Non-cleavable Linker Antibodies Linkerless Antibodies
- VC (Valine-Citrulline) Sulfo-SPDB (N-Succinimidyl 4-[2-pyridyldithio]-2-sulfobutanoate) VA (Valine-Alanine) Hydrazone Linkers Disulfide Linkers Peptide Linkers Others
- MMAE (Monomethyl Auristatin E) MMAF (Monomethyl Auristatin F) DM4 (Maytansine Derivative) Camptothecin Derivatives PBD (Pyrrolobenzodiazepine) Dimers SN-38 (Topoisomerase I Inhibitor) Others
By Payload Type
- MMAE/Auristatin Calicheamicin Maytansinoids PBD Dimers Camptothecin Derivatives SN-38 Other Payload Type
By Application
- Blood Cancer
- Leukemia Lymphoma Multiple Myeloma
By End-User
- Hospitals and Specialty Cancer Centers Biotechnology and Pharmaceutical Companies Academic and Research Institutes Contract Research Organizations (CROs) Other End Users
Click to Request Sample Report and Drive Impactful Decisions:
Regional Analysis
North America is projected to dominate the global ADC market with a 42.7% share in 2024, driven by high cancer incidence and advanced healthcare systems. The pharma industry in this region is strong and the efficient working of the regulatory bodies, including the FDA, and the speedy processes related to clinical trials enhance the market domination.
Further, strong university-industry interface, ongoing improvement in ADC technology, the North American region's promising novel cancer therapies, and the increasing popularity of ADC therapies collectively strengthen the region's stance and provide it a firm hold over the ADC market.
By Region
North America
- The U.S. Canada
Europe
- Germany The U.K. France Italy Russia Spain Benelux Nordic Rest of Europe
Asia-Pacific
- China Japan South Korea India ANZ ASEAN Rest of Asia-Pacific
Latin America
- Brazil Mexico Argentina Colombia Rest of Latin America
Middle East & Africa
- Saudi Arabia UAE South Africa Israel Egypt Rest of MEA
Discover additional reports tailored to your industry needs
- Urgent Care Apps Market size is expected to hold a market value of USD 3.3 billion in 2024 and is projected to show subsequent growth with a market value of USD 80.3 billion by the end of 2033 at a CAGR of 42.5%. Automated Data Processing Market size is expected to reach a value of USD 1,925.1 million in 2024, and it is further anticipated to reach a market value of USD 9,711.4 million by 2033 at a CAGR of 19.7%. Cholesterol Testing Market size is expected to reach a value of USD 109.8 billion in 2024, and it is further anticipated to reach a market value of USD 247.5 billion by 2033 at a CAGR of 9.4%. Acute Kidney Injury Treatment Market is projected to reach USD 1,944.4 million by the end of 2024 and grow exponentially until an anticipated value of USD 3,818.9 million in 2033 at a CAGR of 7.8%. Blood Sensor Market size is expected to reach a value of USD 12.6 billion in 2024, and it is further anticipated to reach a market value of USD 28.4 billion by 2033 at a CAGR of 9.4%. Veterinary Monitoring Equipment Market size is expected to reach a value of USD 2,533.6 million in 2024, and it is further anticipated to reach a market value of USD 5,907.5 million by 2033 at a CAGR of 9.9%. Ultrasonic Scalpels Market size is expected to reach a value of USD 2,397.6 million in 2024, and it is further anticipated to reach a market value of USD 5,089.1 million by 2033 at a CAGR of 8.7%. Revenue Cycle Management Market size is expected to reach a value of USD 326.4 billion in 2024, and it is further anticipated to reach a market value of USD 936.3 billion by 2033 at a CAGR of 13.1%. Respiratory Disease Vaccine Market size is expected to reach a value of USD 102.3 billion in 2024, and it is further anticipated to reach a market value of USD 125.3 billion by 2033 at a CAGR of 2.3%. Pediatric Medical Device Market size is expected to reach a value of USD 34.9 billion in 2024, and it is further anticipated to reach a market value of USD 70.3 billion by 2033 at a CAGR of 8.1%.
Recent Developments in the Antibody Drug Conjugate Market
2024
- July: Pfizer received FDA approval for a new ADC targeting a specific biomarker in triple-negative breast cancer, providing a novel treatment option for this challenging cancer subtype. June: Roche announced promising Phase III trial results for their ADC targeting HER2-positive gastric cancer, demonstrating improved overall survival compared to standard chemotherapy.
2023
- December: Seattle Genetics obtained EMA approval for their ADC targeting relapsed and refractory multiple myeloma, marking its debut in the European market. November: AstraZeneca expanded its ADC manufacturing capabilities with a new state-of-the-art facility to meet the increasing global demand. October: Daiichi Sankyo formed a strategic partnership with Scripps Research Institute to develop next-generation ADCs featuring innovative payloads and linker technologies. September: GlaxoSmithKline initiated a Phase I clinical trial for a new ADC targeting a unique antigen in small-cell lung cancer, reflecting the growing pipeline of ADCs across various cancer types. August: Merck & Co. presented data at the American Society of Clinical Oncology (ASCO) showing their ADC's potential when combined with an immune checkpoint inhibitor, resulting in enhanced anti-tumor activity. July: Bristol-Myers Squibb launched a Phase II trial for their ADC aimed at treating metastatic colorectal cancer, addressing a significant unmet need in this patient group. June: Novartis announced that their leading ADC candidate received orphan drug designation for a rare sarcoma, potentially accelerating its development and approval. May: AbbVie secured breakthrough therapy designation from the FDA for their ADC targeting CD123 in acute myeloid leukemia, highlighting its potential to transform treatment for this aggressive cancer.
About Dimension Market Research (DMR)
Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world.
We also believe that our clients don't always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.
CONTACT: United States 957 Route 33, Suite 12 #308 Hamilton Square, NJ-08690 Phone No.: +1 732 369 9777, +91 88267 74855 ...
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment